The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.
 
Ferdinandos Skoulidis
Stock and Other Ownership Interests - BioNTech; Moderna Therapeutics
Honoraria - Curio Science; DAVA Oncology; ESMO; IDEOlogy Health; Intellisphere; Intellisphere; Japanese Lung Cancer Society; McGill Universite de Montreal; Medscape; MJH Life Sciences; Moving Innovation and Technology; PER; Physicans' Education Resource; RV Mais
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; BergenBio; Bridgebio; Bristol Myers Squibb Foundation; Calithera Biosciences; Genmab; Guardant Health; Hookipa Pharma; Intellisphere; Lilly; Lilly; Medscape; Merck; Navire; Novartis; Novocure; Regeneron; Revolution Medicines; Roche/Genentech; Tango Therapeutics
Research Funding - AIMM Therapeutics (I); Amgen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst)
Travel, Accommodations, Expenses - American Association for Cancer Research; Curio Science; Dava Oncology; IASLC; IDEOlogy Health; MI&T; MJH Life Sciences; PER
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen Oncology; Jazz Pharmaceuticals; Pfizer; Regeneron; Regeneron
Consulting or Advisory Role - Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; BerGenBio; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; Genmab; Gilead Sciences; Grid Therapeutics; IO Biotech; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Novartis; Novocure; Pfizer; PharmaMar; Puma Biotechnology; RAPT Therapeutics; Regeneron; Rgenix; Summit Therapeutics; Systimmune; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; EMD Serono; Genentech; Jazz Pharmaceuticals; Merck; Mirati Therapeutics; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Edward Garon
Consulting or Advisory Role - ABBVIE/ABBOTT; ArriVent Biopharma; AstraZeneca; Bayer; Bicycle Therapeutics; Black Diamond Therapeutics; BridgeBio Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; GlaxoSmithKline; Hexagon; I-Mab; IO Biotech; ITeos Therapeutics; LianBio; Merck; Novartis; Nuvalent, Inc.; Oxford BioTherapeutics; Pfizer; Regeneron; Samsung Bioepis; Sanofi; SERVIER; Strata Oncology; Synthekine; Transcode; Verastem
Research Funding - ABL Bio (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer (Inst); BridgeBio Pharma; Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Synthekine (Inst); TILT Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
 
Ticiana Leal
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca; Black Diamond Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Catalyst Pharmaceuticals; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Merck; Molecular Partners; Naterra; Novocure; Novocure; Nuvation Bio; OncoC4; Oncohost; Pfizer; Roche; Summit Therapeutics; Synthekine; Verastem
Research Funding - Daiichi Sankyo/Astra Zeneca (Inst)
Travel, Accommodations, Expenses - Amgen; Novocure
 
Jacob Kaufman
Honoraria - AstraZeneca; Johnson & Johnson
 
Stephen Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Ellipses Pharma; Genentech; Gilead Sciences; GlaxoSmithKline; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Merus; MSD Oncology; Natera; Novartis; Nuvalent, Inc.; OSE Immunotherapeutics; Pfizer; PharmaMar; Regeneron; Revolution Medicines; Systimmune; Takeda; Yuhan
Research Funding - Abbvie (Inst); Alkermes (Inst); AstraZeneca (Inst); Avenzo (Inst); BioNTech SE (Inst); Cogent Biosciences (Inst); Duality Biologics (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Henlius (Inst); MediLink (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); Nuvation Bio (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); Synthekine (Inst); Systimmune (Inst)
 
Eric Nadler
Consulting or Advisory Role - Johnson & Johnson; Merck; Pfizer
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Pfizer; Regeneron
 
Sandip Pravin Patel
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Compugen; Iovance Biotherapeutics (Inst); Lilly; Lilly; Nektar; Novartis; Pfizer; Roche/Genentech; Tempus
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - A2Bio (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Solange Peters
Honoraria - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Fishawack Facilitate (Inst); Foundation Medicine (Inst); GlaxoSmithKline; Illumina (Inst); Imedex (Inst); Incyte (Inst); Ipsen (Inst); medscape (Inst); Medtoday (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); OncologyEducation (Inst); Peerview (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Sanofi (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Biocartis (Inst); Bioinvent (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); F-Star Biotechnology (Inst); Foundation Medicine (Inst); Genzyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HUTCHMED (Inst); Illumina (Inst); Incyte (Inst); Ipsen (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Nuvation Bio (Inst); Nykode Therapeutics (Inst); Nykode Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Promontory Therapeutics (Inst); Qlucore (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst); Zymeworks (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MJH Life Sciences; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology; ESMO; ESMO Open Associate Editor; ETOP Scientific chair; JTO Past Deputy Editor; Oncosuisse President; SAMO President; Swiss Cancer League Vice-President
 
Biagio Ricciuti
Honoraria - Targeted Oncology
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Guidepoint Inc; Regeneron
Research Funding - AstraZeneca (Inst)
 
Tarek Mekhail
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Regeneron
Consulting or Advisory Role - Johnson & Johnson; Lilly
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Merck; Regeneron
 
Ajeet Gajra
Honoraria - Cardinal Health
Consulting or Advisory Role - AstraZeneca; BeiGene; Cardinal Health; Foundation Medicine; G1 Therapeutics; Genentech; Geron; Johnson & Johnson/Janssen; Nuvation Bio; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Celgene/Juno (Inst); Jazz Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Cardinal Health
Other Relationship - EMOL Health; Exigent Research; Quality Cancer Care Alliance
(OPTIONAL) Uncompensated Relationships - Athelo Health
 
Eric McGary
No Relationships to Disclose
 
Vu Phan
Research Funding - Abbvie; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; AVEO; BeiGene; Biostar Pharma; Celgene; Coherus BioSciences; Eisai; Genentech; Genmab; GlaxoSmithKline; IgM Biosciences; Janssen; Krystal Biotech; Lantern Pharma; Merck; Mirati Therapeutics; Pfizer; Regeneron; Roche; Seagen; Stemline Therapeutics; Tempus; Trios; Xencor
 
James Stevenson
Honoraria - MJH Life Sciences
Consulting or Advisory Role - OptumHealth
Research Funding - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Henlius (Inst); Merck Sharp & Dohme (Inst); PrECOG (Inst)
 
Richard Lynen
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Ugochinyere Emeribe
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Aida Myftiu
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Ashish Gautam
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
John Heymach
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; ALK Positive; ArriVent Biopharma; AstraZeneca; BioNtech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; ModeX Therapeutics; Novartis; Ottimo Pharma; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics; Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations; Patents pending regarding classification of EGFR mutations; Patents pending regarding subtyping of SCLC lung cancer.